Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG

J Clin Neurosci. 2017 Apr:38:71-73. doi: 10.1016/j.jocn.2016.12.022. Epub 2017 Jan 19.

Abstract

There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.

Keywords: Azathioprine; MOG-IgG; Multiple sclerosis; Pediatric.

Publication types

  • Case Reports

MeSH terms

  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Azathioprine / therapeutic use*
  • Child
  • Humans
  • Immunoglobulin G / blood*
  • Immunoglobulin G / immunology
  • Immunosuppressive Agents / therapeutic use*
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Myelin-Oligodendrocyte Glycoprotein / blood*
  • Myelin-Oligodendrocyte Glycoprotein / immunology

Substances

  • Autoantibodies
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Myelin-Oligodendrocyte Glycoprotein
  • Azathioprine